---
layout: default
title: Phenobarbital
parent: Model Prediction Only (L5)
nav_order: 614
evidence_level: L5
indication_count: 10
---

# Phenobarbital
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Phenobarbital: From Epilepsy (Established Use) to Trigeminal Nerve Neoplasm (Predicted)

## One-Sentence Summary

Phenobarbital is a barbiturate anticonvulsant/sedative-hypnotic long used for seizure disorders, though no active Canadian market authorization is on file in this Evidence Pack. The TxGNN model predicts a possible link to **Trigeminal Nerve Neoplasm**, but this direction is currently supported by **0 clinical trials** and only **1 tangentially related publication**, which the evidence review flags as a likely ontology/label mismatch rather than genuine supporting evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in the Canadian regulatory data on file (no licenses recorded). Phenobarbital is broadly known as a barbiturate anticonvulsant/sedative-hypnotic used for epilepsy and seizure disorders. |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed (Not marketed) |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for this candidate (flagged as a High-severity data gap — DG002). Based on well-established pharmacology, phenobarbital is a barbiturate that acts as a positive allosteric modulator of the GABA-A receptor, producing anticonvulsant, sedative, and hypnotic effects; it has long been used to manage seizure disorders.

For this specific predicted pairing, the evidence review found **no direct mechanistic link** between phenobarbital and trigeminal nerve neoplasm. The single associated publication is a 1997 case series on Sturge-Weber syndrome — a condition involving facial vascular malformation combined with seizures — which is not a study of trigeminal nerve tumors. This strongly suggests the TxGNN prediction reflects an **ontology/label mismatch** (disease-term confusion in the knowledge graph) rather than a genuine biological or clinical signal.

Given the absence of clinical trials, absence of a plausible mechanism, and the mismatch in the sole literature reference, this prediction should be treated as speculative and not mechanistically well-founded at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9157801](https://pubmed.ncbi.nlm.nih.gov/9157801/) | 1997 | Case Series | Anales españolas de pediatría | Retrospective review of 14 Sturge-Weber syndrome cases (facial vascular malformation with epilepsy); does not address trigeminal nerve neoplasm treatment — likely an ontology/label mismatch rather than relevant evidence. |

---

## Canada Market Information

No Canadian market authorizations (DINs) are currently on file for this drug. Market status: **Not Marketed** (0 total licenses).

---

## Safety Considerations

Please refer to the package insert for safety information. (TFDA/product monograph warnings and contraindications are an open, Blocking-severity data gap — DG001 — and drug interaction lookup returned no results.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication is supported only by a model score (Evidence Level L5), with zero clinical trials and a single literature reference that appears mismatched to the actual disease concept rather than genuinely relevant. Combined with the lack of a plausible mechanistic rationale and zero Canadian market presence, there is currently no basis to advance this candidate beyond an exploratory research flag.

**To proceed, the following is needed:**
- Confirmed mechanism of action data (DG002) to assess biological plausibility for trigeminal nerve neoplasm
- TFDA/product monograph warnings and contraindications (DG001, Blocking — required before any S1 safety screening)
- A corrected, ontology-verified literature search specifically for trigeminal nerve neoplasm (not seizure-related terms) to determine whether any genuine evidence exists
- Note: within this same Evidence Pack, two other candidates — *thinking seizures* (rank 6) and *reading seizures* (rank 8) — carry stronger evidence (L3, decision stage S1, "Research Question") and may be better near-term candidates for further investigation than this top-ranked but ontology-mismatched prediction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

